Orrick represented Ipsen in the transaction. Ipsen, a global biopharmaceutical company with a focus on bringing transformative medicines to patients in oncology, rare diseases and neuroscience,…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
